FundedIQ
Biotechnology

Insempra

Insempra is a biotechnology company that offers businesses the opportunity to revamp their ingredient lists with high-quality products created in partnership with nature. Traditionally, companies have heavily relied on petrochemicals and harmful practices that have harmed the environment and depleted natural resources. However, with the growing concerns over environmental issues, changing consumer preferences, and stricter regulations, there is a significant shift towards sustainable ingredients in industries like beauty, personal care, food, nutrition, and fashion. Insempra's advanced technology platform allows for the production of superior natural ingredients on a large scale, assisting leading brands in transforming their products to meet these new demands. Our goal is to work together towards a more sustainable future.

insempra.bio Planegg, Germany 11-50 employees
Total raised
$21.6M
Latest round: +1250% of prior total
Rounds
2
Latest
Series A
May 2024

Insempra is a biotechnology company that offers businesses the opportunity to revamp their ingredient lists with high-quality products created in partnership with nature. Traditionally, companies have heavily relied on petrochemicals and harmful practices that have harmed the environment and depleted natural resources. However, with the growing concerns over environmental issues, changing consumer preferences, and stricter regulations, there is a significant shift towards sustainable ingredients in industries like beauty, personal care, food, nutrition, and fashion. Insempra's advanced technology platform allows for the production of superior natural ingredients on a large scale, assisting leading brands in transforming their products to meet these new demands. Our goal is to work together towards a more sustainable future.

Insempra has raised $21.6M across 2 rounds. Its most recent round was a Series A of $20.0M in May 2024. Full funding history, investors, and team are detailed below.

Funding history

2 rounds · 1 visible Unlock with plan

2 rounds on record — latest round shown, the rest unlock with a paid plan.

Date
Round
Amount
Lead investor
May 8, 2024
Series A
$20.0M

Unlock 1 earlier round — dates, amounts, round types — plus the lead investor for every round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Insempra is featured in

Similar companies

smartbax

smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.

Seed
HMNC Brain Health
Series B $50.0M
Pacifico Biolabs

Pacifico Biolabs offers fermentation biotechnology for development, production and distribution of sustainable and food alternatives.

Series A $8.1M
NVision Imaging Technologies
Series B $38.0M
NanoStruct

NanoStruct is a biotechnology company that develops nanostructured sensor chips to identify bacteria and pathogens in food.

Seed $3.1M
Tacalyx

Tacalyx, a company originating from Max-Planck-Institute of Colloids and Interfaces in Potsdam, Germany, is dedicated to researching Tumor-Associated Carbohydrate Antigens (TACAs) as a potential new target for cancer therapy. TACAs are expressed specifically in tumors due to abnormal glycosylation, and contribute to processes like metastasis, angiogenesis, and immune suppression. Tacalyx utilizes advanced carbohydrate synthesis technology to create pure TACA structures, which are then used to develop antibodies for innovative cancer treatments.

Seed
Primogene

Primogene is a biotechnology company that provides ingredient development, bioprocess manufacturing, and scalable production.

Seed $4.8M
mbiomics

Mbiomics is a company in the field of biotechnology.

Series A $12.0M
EVANIUM Healthcare

At EVANIUM, we make plant compounds like polyphenols and flavonoids more effective by improving their solubility, stability, and absorption. Our OPTISOLV® Technology helps deliver natural actives into food, nutraceuticals, pharmaceuticals, and personal care products — more effectively and efficiently. Our goal is to support brands in creating their next product innovation. Developed in Germany. Produced in Europe.

Seed $2.6M
Picea Biosolutions

Picea Biosolutions is a biotechnology firm. Based on their core platform technology, they develop tailored expression systems for enzymes from picoliter to large-scale fermentation. They are building on their experience in engineering a wide range of industrial organisms including bacteria, yeast, and filamentous fungi. Their customized enzyme solutions are applicable across industries such as circular economy, food, and feed. Picea Biosolutions is headquartered in Offenburg, Baden-Wurttemberg and was founded in 2022.

Series Unknown $310k
Kupando

KUPANDO is a pioneering biopharmaceutical firm that is developing TLR 4/7 agonists to boost innate immunity. The company's mission is to provide cancer patients with not only safe but also inexpensive immunotherapy, as well as to produce immunostimulatory drugs capable of preventing infectious illnesses.

Series A $11.5M
iDEL Therapeutics

iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.

Seed $10.4M
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.